Explore qualified clinical-grade peptide active pharmaceutical ingredients (APIs) and research analogs engineered through robust automated solid-phase platforms.
Hexarelin (Examorelin; CAS 140703-51-1) is a synthetic hexapeptide recognized in endocrinology and cellular pharmacology as one of the most potent, stable growth hormone secretagogues (GHS) belonging to the ghrelin mimetic class.
Empirical formula: C47H58N12O6. Structurally defined as a synthetic hexapeptide incorporating unnatural D-amino acids: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The inclusion of D-Trp and D-Phe enhances metabolic stability against endogenous aminopeptidases.
High affinity for the pituitary Growth Hormone Secretagogue Receptor 1a (GHSR-1a), inducing IP3/DAG cascades and intracellular Ca2+ mobilization. Uniquely binds CD36 (scavenger receptor type B), mediating independent cardioprotective actions.
Synthesized through modern automated orthogonal SPPS protocols on Rink Amide AM resin. RP-HPLC purification utilizing dynamic axial compression (DAC) systems guarantees total individual impurity levels below 0.5% with TFA or acetate ion exchange.
Hexarelin functions beyond basic ghrelin mimicking. Unlike native ghrelin, Hexarelin does not require post-translational n-octanoylation at serine-3 for receptor activation, resulting in exceptional structural integrity during lyophilization and extended room-temperature handling. Extensive preclinical assays confirm that Hexarelin activates signal transducers including extracellular signal-regulated kinases (ERK1/2) and protein kinase B (Akt/PKB), facilitating downstream mitochondrial preservation, cardioprotection during ischemic reperfusion injury, and lean musculoskeletal muscle cell regeneration.
Hangzhou Thinheal Pharma-Tech represents China's advanced biopharmaceutical manufacturing tier, integrating raw material verticality, multi-ton synthesis facilities, and rigorous QA architecture.
Direct upstream synthesis of Fmoc-protected D-amino acids (Fmoc-D-Trp-OH, Fmoc-D-Phe-OH), specialized condensation activators (HATU, HBTU, DIC/OxymaPure), and Rink Amide linkers completely insulates production cycles from third-party supply chain bottlenecks.
Our automated solid-phase glass reactors range from 50L pilot scale up to 1000L commercial-scale vessels. High-throughput synthesis ensures annual output capacity exceeding multi-ton metrics, fulfilling both small gram CRO orders and metric-ton generic commercial campaigns.
Continuous-flow deprotection technologies and optimized cleavage cocktails (TFA/EDT/water/TIS) yield raw crude purities >88%, drastically reducing prep-HPLC solvent consumption and delivering 35-50% operational cost efficiency compared to Western contract CDMO facilities.
Thinheal provides full CMC regulatory support dossiers (CTD format), comprehensive impurity profiling, validated analytical methods, stability testing under ICH conditions (25°C/60% RH and 40°C/75% RH), and ready access for customer on-site and remote audits.
Every manufactured batch of Hexarelin is released accompanied by lot-specific analytical certificates conforming to international pharmacopeia monographs and ISO 9001/cGMP guidelines.
| Analytical Parameter | Release Specification Standard | Test Methodology | Quality Conformance |
|---|---|---|---|
| Chemical Structure & Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | High-Resolution MS & 500MHz 1H-NMR | Conforms |
| HPLC Chromatographic Purity | ≥ 98.0% (Research) / ≥ 99.0% (Clinical API) | RP-HPLC (C18 Column, 220nm detection) | >99.2% Typical |
| Molecular Weight Confirmation | 887.04 ± 0.5 Da (Monoisotopic Mass) | ESI-MS / MALDI-TOF | Matched |
| Peptide Content (Net Base) | ≥ 80.0% to 88.0% | Elemental Analysis / Amino Acid Analysis | Pass |
| Counter-Ion Profiling | Acetate (≤ 12.0%) or Trifluoroacetate (≤ 1.0%) | Ion Exchange Chromatography (IC) | Customizable |
| Moisture Content | ≤ 5.0% (Lyophilized state) | Karl Fischer Coulometric Titration | ≤3.2% |
| Bacterial Endotoxins | ≤ 5.0 EU/mg (Bio-research and formulation API) | Chromogenic LAL Kinetic Method | <2.0 EU/mg |
| Residual Solvents (GC-HS) | Acetonitrile <410ppm, DCM <600ppm, DMF <880ppm | Headspace Gas Chromatography | USP <467> |
Custom synthesis pricing fluctuates depending on chosen counter-ion (Acetate vs. TFA salt exchange), packaging specifications (sterile aliquot vs. bulk lyophilized cake in HDPE bottles), and required analytical documentation (CoA, LC-MS, HPLC, NMR, Residual Solvents). Below represents indicative procurement tiers for pharmaceutical and biotech research partners:
Includes standard CoA, RP-HPLC & MS identity data. Recommended for initial formulation screening.
TFA removal / Acetate conversion options. Bioburden and Karl Fischer testing inclusion.
Batch record retention, endotoxin certification ≤5 EU/mg, and custom lyophilization sizing.
Dedicated synthesis slots, customized impurity profile thresholds, and full regulatory CMC supply support.
The global peptide therapeutics sector is expanding past $50 Billion USD, propelled by GLP-1/GIP breakthroughs and regenerative secretagogues. Manufacturers must adapt to green chemistry initiatives and automated purification matrices.
Historic peptide manufacturing generated tons of DMF and NMP chemical waste. Thinheal adopts greener solvent formulations such as 2-MeTHF and Cyrene alongside closed-loop continuous solvent distillation, reducing carbon footprint while cutting raw overhead costs for our global buyers.
While long-chain GLP-1 analogues like Semaglutide utilize combined fermentation-chemical fragment condensation, short-chain hexapeptides like Hexarelin are purely synthesized via SPPS. This eliminates host cell protein (HCP) and DNA contamination risks entirely.
Global authorities (FDA, EMA, NMPA) demand rigorous detection of trace immunogenic impurities, particularly peptide deletions and D-enantiomeric epimers. Thinheal applies orthogonal UPLC-MS/MS and circular dichroism (CD) to characterize high-order structures.
Preclinical literature demonstrates Hexarelin’s distinct physiological advantages over traditional growth hormone secretagogues and native ghrelin across three distinct biological axes.
Unlike non-peptide GHS molecules, Hexarelin binds directly to myocardial CD36 receptors. This pathway mitigates ischemia-reperfusion injury, reduces post-infarction left ventricular remodeling, suppresses cardiomyocyte apoptosis, and significantly preserves coronary arterial perfusion during myocardial stress.
Hexarelin induces massive, transient growth hormone surges by overcoming somatostatin inhibitory tone at the pituitary level. This systemic elevation stimulates hepatic production of Insulin-Like Growth Factor 1 (IGF-1), speeding structural collagen synthesis and somatic tissue rehabilitation without altering baseline cortisol/ACTH persistently.
Through down-regulation of muscle-specific E3 ubiquitin ligases (MuRF-1 and Atrogin-1), Hexarelin blocks hyper-catabolic proteolysis. Preclinical sarcopenia and burn trauma models demonstrate noticeable restoration of myofiber cross-sectional area and lean skeletal muscle mass retention.
When qualifying Chinese contract peptide manufacturers, procurement teams must enforce standard operating verifications exceeding simple pricing per gram.
Audit resin substitution values and swelling volume in DCM/DMF. Sub-optimal loading causes aggregation during hexapeptide chain elongation, generating problematic His-truncated deletions.
Demand raw integration files, not just isolated percentages. Confirm baseline resolution between Hexarelin and its diastereomers (D-Phe vs L-Phe epimers) with gradient RP-HPLC.
Residual Trifluoroacetate (TFA) salt can introduce in-vitro cytotoxicity in fragile cellular assays. Specify lyophilized acetate exchange verified below 1.0% residual TFA limits.
For pre-clinical in-vivo preparations, strict LAL testing is paramount. Verify the manufacturing water system utilizes pharmaceutical-grade USP WFI (Water for Injection) systems.
Ensure heavy metals and trace catalysts (Palladium, Lead, Arsenic) comply with ICH Q3D requirements via Inductively Coupled Plasma Mass Spectrometry (ICP-MS).
Ensure manufacturer utilizes calibrated dry ice and phase-change thermal containers with real-time temperature tracking loggers throughout door-to-door international transport.
Detailed commercial, chemical, and shipping clarifications to accelerate your vendor evaluation process.
Direct factory pricing, dedicated account managers, and immediate technical review of your custom peptide specifications.
Complementary generic APIs, gastrointestinal agonists, and structural regulatory hormone analogues manufactured under identical rigorous quality control architecture.
Thin